Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434977 | 0.95 | NPSR1 (0.42) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL1435037 | 0.91 | LMNA (0.44) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL1434486 | 0.90 | NPSR1 (0.42) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL1434978 | 0.85 | NPSR1 (0.38) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL14035627 | 0.81 | NPSR1 (0.35) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL1434947 | 0.80 | LMNA (0.40) | NPSR1LMNACYP4F2CYP4A11MEN1 | |
| Hydrochloric Acid SCHEMBL1435952 | 0.77 | NPSR1 (0.42) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| Hydrochloric Acid SCHEMBL3856698 | 0.77 | NPSR1 (0.42) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL6143483 | 0.75 | NPSR1 (0.46) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL3856705 | 0.74 | NPSR1 (0.44) | NPSR1LMNACYP4F2CYP4A11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684745-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-1684745-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1506000-B9 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1506000-B9 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1506172-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1506172-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1506000-B1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1506000-B1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1506172-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004032827-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | CAMPBELL JEFFREY ALLEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | HCCS, ANPEP, DNPEP | NPSR1 508/4885LMNA 4281/4885CYP4F2 2912/4885 |
| US-20020111313-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | NPSR1 1741/4885LMNA 3808/4885CYP4F2 2888/4885 |
| US-20040048802-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | NPSR1 1741/4885LMNA 3808/4885CYP4F2 2888/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | NPSR1 1047/4885LMNA 3287/4885CYP4F2 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.